Showing results (811-820 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|May 1, 2020
Analysis of the economic situation of the South East European pharmaceutical industryJovana Milenković, Dragana LakićJournal of Medical Economics|May 16, 2020
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United StatesRachael Louise Slater, Yizhen Lai, Yichen Zhong, et al.Journal of Medical Economics|May 20, 2020
Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs)Damemarie Paul, Dhaval Patil, Laura McDonald, et al.Journal of Medical Economics|May 14, 2020
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspectiveHongbo Yang, Yanni Hao, Xinglei Chai, et al.Journal of Medical Economics|June 10, 2015
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in EnglandMaciej J Maruszczak, Stephen M Montgomery, Matthew J S Griffiths, et al.Journal of Medical Economics|July 24, 2015
Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapyJoseph F Dasta, Dominic Pilon, Samir H Mody, et al.Journal of Medical Economics|June 30, 2015
Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorderZheng-Yi Zhou, Shawn Sun, Pooja Chopra, et al.Journal of Medical Economics|June 10, 2015
Modeling the clinical and economic implications of obesity using microsimulationW Su, J Huang, F Chen, et al.Journal of Medical Economics|June 6, 2015
Costs and absence of HCV-infected employees by disease stageRobert W Baran, Jennifer C Samp, David R Walker, et al.Journal of Medical Economics|April 28, 2020
Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United StatesJacqueline Nicholas, Rachel Halpern, Marina Ziehn, et al.Pageof 241